A smoking pivot that actually worked

Today, I’m looking at Philip Morris International (PMI). The are "the" cigarette company that’s transitioning more and more of their company into “smoke-free” products.

Their pivot from cigarettes to heated tobacco (eg. IQOS) and nicotine pouches (eg. ZYN) is one of the visible in recent times. If you're like me, you've noticed these smoke-free products taking up more and more shelf space at convenience stores and other places where cigarettes are sold.

And you may likely know one or more people who are using these products today. I certainly do (even if I don't myself, yet.....).

Here are a few quick takeaways:

• The recurring model: They make devices, but the real money comes from the consumables. A razor-and-blades play with big gross margins.

• Smoke-free growth: 41% of total revenue now comes from smoke-free products, up from 20% in 2020.

• Margin story: Overall gross margin sits near 67%, and the smoke-free line is even higher. This is a rare case where the replacement product is more profitable than the original.

• The downside: Regulation and litigation risk never go away, and their 2021 attempt at healthcare diversification (Vectura, an asthsma inhaler company) backfired as they sold it and a few other "smoke-free wellness" brands in 2024 for a $600 million loss.

One of the main takeaways from Philip Morris is the fact that one of its primary competitive edges (selling addicting products) isn't applicable to most of us! If we want to stay out of jail...

With that said, I think a powerful takeaway is the value that comes with having a consumable product or service instead of one-off versions of such.

I'll talk see you tomorrow!

Nick

TL;DR

• PMI is transitioning from a cigarette giant into a global leader in smoke-free nicotine products like IQOS and ZYN.

• Smoke-free products accounted for 39% of revenue in 2024 and 41% by mid-2025, showing real traction in the pivot.

• PMI’s model is a masterclass in consumables economics: the device brings you in, but the refills print the money.

• The company’s scale, brand strength, and regulatory know-how are its biggest moats.

• Lesson: Own the recurring unit, and don’t let regulatory barriers scare you—they can turn into your moat.

The 30,000-Foot View

• Business Model: PMI manufactures and sells cigarettes and smoke-free nicotine products globally. The company earns recurring revenue from consumables—heatsticks for IQOS devices and nicotine pouches like ZYN.

• Revenue Mix: 2024: 61% combustible, 39% smoke-free. 2025 YTD: 59% combustible, 41% smoke-free.

• Key Stats:

  • Market Cap: $245.8B (Oct 2025)

  • TTM Revenue: $39.99B

  • Gross Margin: 66.9%

  • Net Income (TTM): $8.6B

  • Employees: ~83,100

  • Industry: Tobacco / Consumer Staples

PMI’s story is one of controlled reinvention. Rather than disrupt itself overnight, it’s shifting profit pools from cigarettes to smoke-free products through pricing, acquisition, and distribution muscle.

Company History

• 1847: Founded as a London tobacconist.

• 2008: Spun off from Altria to focus on international markets.

• 2014–2016: IQOS launches in Japan and Italy, establishing a new category of heated tobacco.

• 2021: Jacek Olczak becomes CEO, accelerating the smoke-free transition.

• 2022: Acquires Swedish Match, adding ZYN pouches and U.S. market access.

• 2024: Gains full U.S. rights to commercialize IQOS from Altria.

• 2025: Launches IQOS in Texas; smoke-free reaches 41% of total revenue.

Show Me the Money

Stand-Out Financial Features:

• Smoke-free products are margin-accretive and now make up 41% of revenue.

• Mid-60s gross margins reflect pricing power and manufacturing efficiency.

• Capex remains focused on smoke-free expansion, particularly ZYN capacity in the U.S.

• Net debt remains elevated from the Swedish Match acquisition but is well covered by cash flows.

Financial Data

The N.O.O.B. Nine — Competitive Powers

The Nerd Out on Business Nine is made up of Hamliton Helmer's famous "7 Powers" of competitive advantage (Scale Economies, Network Economies, Counter-Positioning, Switching Costs, Branding, Cornered Resource, and Process Power) combined with two of my own (Data Flywheel and Distribution Advantage).

Average Score: 3.6/5 - A robust moat driven by scale, brand power, and execution discipline.

Memorable Marketing

Approach: PMI operates under heavy advertising restrictions, so it leans on experiential marketing, owned media, and corporate storytelling to position itself as the leader of a “smoke-free future.”

Campaigns:

• Unsmoke Your World (2019–Present)

  • Hook: Reframe tobacco as part of the solution, not the problem.

  • Channel: PR and digital content.

  • Why it worked: Repositioned the brand around transformation.

  • Result: Set the narrative foundation for PMI’s smoke-free pivot.

• IQOS Retail Experience (2016–Ongoing)

  • Hook: Teach the ritual, sell the habit.

  • Channel: Experiential retail and guided demos.

  • Why it worked: Direct education boosted conversion rates in regulated markets.

  • Result: Over 38M smoke-free users by 2024.

• ZYN Blitz (2023–2025)

  • Hook: Rapid U.S. rollout using retail partnerships and influencer marketing.

  • Channel: Retail promotions and sampling.

  • Why it worked: Fast habit adoption and viral buzz.

  • Result: ZYN shipments rose 42% YoY in late 2024.

Tactical Takeaways for Founders:

1. Turn users into educators—guided demos beat ads in regulated markets.

2. Build recurring revenue around a consumable, not a device.

3. Use small test markets to refine price and message before scaling.

4. Corporate narrative can drive real customer pull when ads aren’t allowed.

AI Uses & Opportunities

• Current: Data analytics for logistics, forecasting, and IQOS device diagnostics.

• Potential Future Uses:

  • Predictive inventory allocation before excise tax changes.

  • AI-driven compliance monitoring to spot regulatory risks early.

  • Device telemetry for predictive maintenance and customer engagement.

  • Promotional ROI modeling to optimize spend by channel.

  • AI-driven anti-smuggling and gray-market tracking.

Bumps in the Road

• Regulation: Constant threat of new flavor bans, plain packaging, and tax shifts.

• Litigation: Ongoing lawsuits globally, especially around nicotine health impacts.

• Failed Diversification: The Vectura healthcare acquisition and 2024 divestiture show the limits of non-core ventures.

• FX Risk: Global exposure leads to swings in reported results.

• Execution Risk: U.S. IQOS rollout is slow and heavily regulated.

Your Swipe File

• Own the Consumable: Recurring revenue is powerful.

• Pre-Build Capacity: Invest ahead of demand to stay in stock and scale smoothly.

• Narrative as a Channel: A powerful story can replace expensive advertising.

• Avoid Distraction: Stick to your core; diversification without synergy is a drain.

• Regulation as a Moat: Once you learn to comply, your compliance becomes a barrier to entry.